Rhythm Pharmaceuticals reports preliminary Q4 IMCIVREE revenue $42M
…
50,246$
3,30%
Echtzeit-Aktienkurs Rhythm Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Rhythm Pharmaceuticals Inc. Aktie
Rhythm Pharmaceuticals: Jährliches Umsatzwachstum von fast 70 % durch Adipositas-Therapie
Viele Unternehmen im Megatrend Biopharmazeutika haben durch Donald Trumps Wahlsieg zum US-Präsidenten einen deutlichen Schub erhalten, doch zahlreiche Aktienkurse korrigierten…
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused…
Hungerkontrolle: Der Kampf gegen Adipositas
Rhythm Pharmaceuticals ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Therapien zur Behandlung seltener genetischer Adipositasstörungen konzentriert. Das…
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused…
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript
…
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) and Axovia Therapeutics Ltd. today…
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript
…
Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript
…
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on…
Rhythm Pharmaceuticals CTO sells shares worth over $735k By Investing.com
Rhythm Pharmaceuticals CTO sells shares worth over $735k…
Rhythm Pharmaceuticals executive sells shares worth over $700k By Investing.com
Rhythm Pharmaceuticals executive sells shares worth over $700k…
Rhythm Pharmaceuticals CFO sells shares worth over $600k By Investing.com
Rhythm Pharmaceuticals CFO sells shares worth over $600k…
Rhythm Pharmaceuticals exec sells $627,520 in stock By Investing.com
Rhythm Pharmaceuticals exec sells $627,520 in stock…